CN Patent

CN104644604A — 替格瑞洛倍半水合物胶囊及其制备方法

Assigned to Tianjin Hankang Pharmaceutical Biotechnology Co Ltd · Expires 2015-05-27 · 11y expired

What this patent protects

本发明属于医药技术领域，具体涉及替格瑞洛倍半水合物胶囊及其制备方法，本发明得到的替格瑞洛倍半水合物胶囊，具有的优点：工艺简便，成本低廉，生物利用度高；对血小板聚集的抑制作用，替格瑞洛倍半水合物胶囊提高近10％。本发明还涉及使用这种胶囊治疗心脑血管系统疾病的应用。

USPTO Abstract

本发明属于医药技术领域，具体涉及替格瑞洛倍半水合物胶囊及其制备方法，本发明得到的替格瑞洛倍半水合物胶囊，具有的优点：工艺简便，成本低廉，生物利用度高；对血小板聚集的抑制作用，替格瑞洛倍半水合物胶囊提高近10％。本发明还涉及使用这种胶囊治疗心脑血管系统疾病的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN104644604A
Jurisdiction
CN
Classification
—
Expires
2015-05-27
Drug substance claim
No
Drug product claim
No
Assignee
Tianjin Hankang Pharmaceutical Biotechnology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.